UPDATE: Credit Suisse Raises PT on Ariad Pharmaceuticals, View Remains Cautious

In a report published Monday, Credit Suisse analyst Jason Kantor announced a price target increase from $2.50 to $5.00 at Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA ). The report summary noted, “Iclusig will be made available again in the US in January following the FDA's approval of the new label and the